Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 Oct 2019
Historique:
received: 18 09 2019
revised: 14 10 2019
accepted: 17 10 2019
entrez: 23 10 2019
pubmed: 23 10 2019
medline: 28 2 2020
Statut: epublish

Résumé

Regular aerobic exercise, independently of weight loss, improves metabolic and anti-inflammatory states, and can be regarded as beneficial in counteracting obesity-induced low-grade inflammation. However, it is still unknown how exercise alters immunometabolism in a context of dietary changes. Agonists of the Peroxisome Proliferator Activated-Receptor beta/delta (PPARβ/δ) have been studied this last decade as "exercise-mimetics", which are potential therapies for metabolic diseases. In this study, we address the question of whether PPARβ/δ agonist treatment would improve the immunometabolic changes induced by exercise in diet-induced obese female mice, having switched from a high fat diet to a normal diet. 24 mice were assigned to groups according to an 8-week exercise training program and/or an 8-week treatment with 3 mg/kg/day of GW0742, a PPARβ/δ agonist. Our results show metabolic changes of peripheral lymphoid tissues with PPARβ/δ agonist (increase in fatty acid oxidation gene expression) or exercise (increase in AMPK activity) and a potentiating effect of the combination of both on the percentage of anti-inflammatory Foxp3+ T cells. Those effects are associated with a decreased visceral adipose tissue mass and skeletal muscle inflammation (TNF-α, Il-6, Il-1β mRNA level), an increase in skeletal muscle oxidative capacities (citrate synthase activity, endurance capacity), and insulin sensitivity. We conclude that a therapeutic approach targeting the PPARβ/δ pathway would improve obesity treatment.

Identifiants

pubmed: 31635041
pii: ijms20205182
doi: 10.3390/ijms20205182
pmc: PMC6829333
pii:
doi:

Substances chimiques

PPAR delta 0
PPAR-beta 0
Thiazoles 0
(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid 4PZK9FJC4Z
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Française de Lutte contre le Dopage
ID : AFLD_2017-00016

Références

Physiol Rev. 2014 Jul;94(3):795-858
pubmed: 24987006
Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):837-43
pubmed: 18043308
JCI Insight. 2017 Feb 9;2(3):e89160
pubmed: 28194435
J Nutr Biochem. 2019 Jul;69:44-52
pubmed: 31048208
Obes Rev. 2009 Mar;10(2):154-67
pubmed: 19021872
J Clin Invest. 2015 Jan;125(1):194-207
pubmed: 25437876
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
Obes Rev. 2016 Dec;17(12):1226-1244
pubmed: 27743411
Nat Med. 2014 Nov;20(11):1327-33
pubmed: 25282359
J Immunol. 2014 Jan 15;192(2):623-9
pubmed: 24323581
Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E586-94
pubmed: 18577694
Front Immunol. 2019 Feb 04;10:115
pubmed: 30778354
Front Immunol. 2017 Nov 27;8:1632
pubmed: 29230216
Eur J Clin Invest. 2017 Aug;47(8):600-611
pubmed: 28722106
J Immunol. 2018 Oct 15;201(8):2215-2219
pubmed: 30209190
Immunology. 2010 Aug;130(4):572-88
pubmed: 20406305
Obes Rev. 2015 Feb;16(2):171-86
pubmed: 25494712
FASEB J. 2016 Mar;30(3):1287-99
pubmed: 26655383
Cell Metab. 2017 Jun 6;25(6):1282-1293.e7
pubmed: 28416194
Sci Rep. 2016 Sep 29;6:34317
pubmed: 27680392
Diabetes. 2018 Mar;67(3):360-371
pubmed: 29233935
Biol Sex Differ. 2019 Apr 3;10(1):16
pubmed: 30944030
Cell. 2008 Aug 8;134(3):405-15
pubmed: 18674809
Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E964-76
pubmed: 23482446
Diabetes. 2013 Apr;62(4):1032-5
pubmed: 23520282
Am J Reprod Immunol. 2018 Mar;79(3):
pubmed: 29315988
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7815-20
pubmed: 18509063
Nat Immunol. 2016 May 19;17(6):618-25
pubmed: 27196520
Int J Mol Sci. 2018 May 25;19(6):null
pubmed: 29799467
J Clin Invest. 2012 Nov;122(11):4105-17
pubmed: 23093780
Immunity. 2017 Sep 19;47(3):406-420
pubmed: 28930657
Exp Clin Endocrinol Diabetes. 2018 Feb;126(2):96-101
pubmed: 28954308
Nat Cell Biol. 2011 Sep 02;13(9):1016-23
pubmed: 21892142
Brain Behav Immun. 2009 Jul;23(5):643-8
pubmed: 19133324
J Immunol. 2011 Mar 15;186(6):3299-303
pubmed: 21317389
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Immunity. 2015 Jan 20;42(1):41-54
pubmed: 25607458
Diabetes. 2018 Feb;67(2):169-179
pubmed: 29358486
Mol Endocrinol. 2011 Sep;25(9):1487-98
pubmed: 21798999
Eur J Appl Physiol. 2013 Jul;113(7):1839-48
pubmed: 23435500
Lancet Public Health. 2017 May 19;2(6):e277-e285
pubmed: 28626830
Int J Obes (Lond). 2015 Nov;39(11):1607-18
pubmed: 26041698
FASEB J. 2003 Dec;17(15):2299-301
pubmed: 14525942
J Allergy Clin Immunol. 2016 May;137(5):1607-1610.e8
pubmed: 26774657
Physiol Genomics. 2008 Feb 19;32(3):360-9
pubmed: 18042831
Am J Physiol Endocrinol Metab. 2012 Jun 15;302(12):E1541-9
pubmed: 22496344
Eur J Immunol. 2017 Feb;47(2):225-235
pubmed: 28054344
Nat Rev Immunol. 2011 Aug 05;11(9):607-15
pubmed: 21818123
Diabetes. 2007 Aug;56(8):2085-92
pubmed: 17519422
Nat Immunol. 2008 Jun;9(6):632-40
pubmed: 18438410
Physiol Behav. 2017 Jul 1;176:174-182
pubmed: 28284880
Biochimie. 2017 May;136:33-41
pubmed: 27939528
Immunity. 2015 Sep 15;43(3):421-34
pubmed: 26377896

Auteurs

Sébastien Le Garf (S)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. sebastien.le-garf@univ-cotedazur.fr.

Joseph Murdaca (J)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. Joseph.MURDACA@unice.fr.

Isabelle Mothe-Satney (I)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. Isabelle.Satney@unice.fr.

Brigitte Sibille (B)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. Brigitte.Sibille@unice.fr.

Gwenaëlle Le Menn (G)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. gwenaelle.lemenn@gmail.com.

Giulia Chinetti (G)

Université Côte d'Azur, INSERM, C3M, CHU, CEDEX 3, 06204 Nice, France. giulia.chinetti@univ-cotedazur.fr.

Jaap G Neels (JG)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. jaap.neels@unice.fr.

Anne-Sophie Rousseau (AS)

Université Côte d'Azur, INSERM, C3M, CEDEX 3, 06204 Nice, France. asrousse@unice.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH